CL2022002341A1 - Compuestos y métodos para modular el empalme - Google Patents
Compuestos y métodos para modular el empalmeInfo
- Publication number
- CL2022002341A1 CL2022002341A1 CL2022002341A CL2022002341A CL2022002341A1 CL 2022002341 A1 CL2022002341 A1 CL 2022002341A1 CL 2022002341 A CL2022002341 A CL 2022002341A CL 2022002341 A CL2022002341 A CL 2022002341A CL 2022002341 A1 CL2022002341 A1 CL 2022002341A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- methods
- modulating splicing
- splicing
- modulating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Replacement Of Web Rolls (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Psychology (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención se refiere a los compuestos y a las composiciones relacionadas que, entre otros, modulan el empalme de ácidos nucleicos, por ejemplo el empalme del pre ARNm, así como los métodos de uso de los mismos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062983541P | 2020-02-28 | 2020-02-28 | |
US202063007333P | 2020-04-08 | 2020-04-08 | |
US202063040484P | 2020-06-17 | 2020-06-17 | |
US202063072790P | 2020-08-31 | 2020-08-31 | |
US202063126492P | 2020-12-16 | 2020-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022002341A1 true CL2022002341A1 (es) | 2023-03-10 |
Family
ID=75143749
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022002342A CL2022002342A1 (es) | 2020-02-28 | 2022-08-26 | Amidas heterociclicas y su uso para modular el empalme |
CL2022002341A CL2022002341A1 (es) | 2020-02-28 | 2022-08-26 | Compuestos y métodos para modular el empalme |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022002342A CL2022002342A1 (es) | 2020-02-28 | 2022-08-26 | Amidas heterociclicas y su uso para modular el empalme |
Country Status (14)
Country | Link |
---|---|
US (2) | US20230365566A1 (es) |
EP (3) | EP4110785A1 (es) |
JP (2) | JP2023515621A (es) |
KR (2) | KR20220159386A (es) |
CN (2) | CN115515679A (es) |
AU (2) | AU2021228767A1 (es) |
BR (2) | BR112022017210A2 (es) |
CA (2) | CA3169709A1 (es) |
CL (2) | CL2022002342A1 (es) |
CO (2) | CO2022013827A2 (es) |
CR (2) | CR20220484A (es) |
IL (2) | IL295956A (es) |
MX (2) | MX2022010683A (es) |
WO (3) | WO2021174163A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3689863A1 (en) | 2017-08-04 | 2020-08-05 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
EP4149937A1 (en) | 2020-05-13 | 2023-03-22 | CHDI Foundation, Inc. | Htt modulators for treating huntington's disease |
IL311132A (en) | 2021-08-30 | 2024-04-01 | Remix Therapeutics Inc | Splicing Modulation Compounds and Methods |
WO2023034812A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
CA3238090A1 (en) * | 2021-11-17 | 2023-05-25 | Chdi Foundation, Inc. | Htt modulators for treating huntington's disease |
WO2023244996A2 (en) * | 2022-06-15 | 2023-12-21 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating huntington's disease |
WO2024086570A1 (en) | 2022-10-17 | 2024-04-25 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
WO2024086569A1 (en) | 2022-10-17 | 2024-04-25 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4809656B2 (ja) * | 2005-09-29 | 2011-11-09 | 富士フイルム株式会社 | ナフタロシアニン色素およびその製造方法 |
TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
SI2049491T1 (sl) * | 2006-08-08 | 2011-05-31 | Millennium Pharm Inc | Heteroarilne spojine uporabne kot inhibitorji e1 aktivirajoäśih encimov |
WO2008040951A1 (en) * | 2006-10-03 | 2008-04-10 | Astrazeneca Ab | Compounds |
WO2009141386A1 (en) * | 2008-05-23 | 2009-11-26 | Novartis Ag | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
EP2435421A1 (en) * | 2009-05-29 | 2012-04-04 | Schering Corporation | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c |
CN102020643A (zh) * | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
TW201202230A (en) * | 2010-05-24 | 2012-01-16 | Mitsubishi Tanabe Pharma Corp | Novel quinazoline compound |
JP6092897B2 (ja) | 2012-02-10 | 2017-03-08 | ピーティーシー セラピューティクス, インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
CA2872989A1 (en) * | 2012-05-09 | 2013-11-14 | Zoetis Llc | Azetidine derivatives as antiparasitic agents |
MY174339A (en) | 2012-08-13 | 2020-04-09 | Novartis Ag | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions |
US9675697B2 (en) * | 2013-03-11 | 2017-06-13 | The Regents Of The University Of Michigan | BET bromodomain inhibitors and therapeutic methods using the same |
KR20140125061A (ko) * | 2013-04-18 | 2014-10-28 | (주)경인양행 | 유기발광 화합물 및 이를 포함하는 유기전계발광소자 |
WO2016004254A1 (en) * | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
CN104341403B (zh) * | 2014-10-10 | 2016-06-22 | 山东盛华电子新材料有限公司 | 一种2,5-二杂环取代萘基噁烷衍生物及其制备方法 |
WO2016128343A1 (en) | 2015-02-09 | 2016-08-18 | F. Hoffmann-La Roche Ag | Compounds for the treatment of cancer |
EP3287463A4 (en) * | 2015-04-24 | 2018-07-11 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof |
US10668171B2 (en) | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
CN110946865B (zh) | 2015-12-10 | 2024-01-26 | Ptc医疗公司 | 用于治疗亨廷顿病的方法 |
US20190119236A1 (en) * | 2016-02-23 | 2019-04-25 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
CA3043755A1 (en) | 2016-11-28 | 2018-05-31 | Ptc Therapeutics, Inc. | Methods for modulating rna splicing |
CA3065547A1 (en) | 2017-06-14 | 2018-12-20 | Ptc Therapeutics, Inc. | Methods for modifying rna splicing |
EP3689863A1 (en) | 2017-08-04 | 2020-08-05 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
CN111373057A (zh) | 2017-09-25 | 2020-07-03 | 斯基霍克疗法公司 | 用于筛选和鉴定剪接调节剂的方法和组合物 |
KR20200142039A (ko) | 2018-04-10 | 2020-12-21 | 스카이호크 테라퓨틱스, 인코포레이티드 | 암 치료용 화합물 |
EP3816160A4 (en) * | 2018-06-27 | 2022-03-16 | Reborna Biosciences, Inc. | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY |
CN109180690A (zh) * | 2018-10-15 | 2019-01-11 | 烟台显华化工科技有限公司 | 一类用作蓝色荧光材料的氮杂芳香化合物及其应用 |
-
2021
- 2021-02-28 CA CA3169709A patent/CA3169709A1/en active Pending
- 2021-02-28 IL IL295956A patent/IL295956A/en unknown
- 2021-02-28 MX MX2022010683A patent/MX2022010683A/es unknown
- 2021-02-28 CA CA3169691A patent/CA3169691A1/en active Pending
- 2021-02-28 IL IL295957A patent/IL295957A/en unknown
- 2021-02-28 EP EP21713822.1A patent/EP4110785A1/en active Pending
- 2021-02-28 KR KR1020227033660A patent/KR20220159386A/ko unknown
- 2021-02-28 AU AU2021228767A patent/AU2021228767A1/en active Pending
- 2021-02-28 WO PCT/US2021/020152 patent/WO2021174163A1/en unknown
- 2021-02-28 US US17/802,719 patent/US20230365566A1/en active Pending
- 2021-02-28 WO PCT/US2021/020154 patent/WO2021174165A1/en active Application Filing
- 2021-02-28 BR BR112022017210A patent/BR112022017210A2/pt unknown
- 2021-02-28 CR CR20220484A patent/CR20220484A/es unknown
- 2021-02-28 EP EP21713824.7A patent/EP4110459A1/en active Pending
- 2021-02-28 MX MX2022010684A patent/MX2022010684A/es unknown
- 2021-02-28 CN CN202180030671.0A patent/CN115515679A/zh active Pending
- 2021-02-28 EP EP21713823.9A patent/EP4110464A1/en active Pending
- 2021-02-28 WO PCT/US2021/020153 patent/WO2021174164A1/en active Application Filing
- 2021-02-28 JP JP2022552209A patent/JP2023515621A/ja active Pending
- 2021-02-28 CN CN202180031467.0A patent/CN115485025A/zh active Pending
- 2021-02-28 AU AU2021228284A patent/AU2021228284A1/en active Pending
- 2021-02-28 CR CR20210483A patent/CR20210483A/es unknown
- 2021-02-28 US US17/802,833 patent/US20240190879A1/en active Pending
- 2021-02-28 KR KR1020227033663A patent/KR20220158238A/ko unknown
- 2021-02-28 JP JP2022552208A patent/JP2023515620A/ja active Pending
- 2021-02-28 BR BR112022017188A patent/BR112022017188A2/pt unknown
-
2022
- 2022-08-26 CL CL2022002342A patent/CL2022002342A1/es unknown
- 2022-08-26 CL CL2022002341A patent/CL2022002341A1/es unknown
- 2022-09-27 CO CONC2022/0013827A patent/CO2022013827A2/es unknown
- 2022-09-27 CO CONC2022/0013832A patent/CO2022013832A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2022002342A1 (es) | 2023-03-17 |
CR20220484A (es) | 2022-12-15 |
IL295957A (en) | 2022-10-01 |
EP4110459A1 (en) | 2023-01-04 |
AU2021228284A1 (en) | 2022-09-29 |
CO2022013832A2 (es) | 2022-10-31 |
EP4110464A1 (en) | 2023-01-04 |
WO2021174165A1 (en) | 2021-09-02 |
BR112022017210A2 (pt) | 2022-10-25 |
US20240190879A1 (en) | 2024-06-13 |
JP2023515621A (ja) | 2023-04-13 |
MX2022010683A (es) | 2023-01-19 |
KR20220158238A (ko) | 2022-11-30 |
CR20210483A (es) | 2022-11-25 |
CO2022013827A2 (es) | 2022-10-31 |
MX2022010684A (es) | 2023-01-19 |
BR112022017188A2 (pt) | 2022-11-08 |
KR20220159386A (ko) | 2022-12-02 |
CN115515679A (zh) | 2022-12-23 |
CA3169691A1 (en) | 2021-09-02 |
WO2021174163A1 (en) | 2021-09-02 |
CN115485025A (zh) | 2022-12-16 |
US20230365566A1 (en) | 2023-11-16 |
JP2023515620A (ja) | 2023-04-13 |
WO2021174164A1 (en) | 2021-09-02 |
AU2021228767A1 (en) | 2022-09-29 |
CA3169709A1 (en) | 2021-09-02 |
EP4110785A1 (en) | 2023-01-04 |
IL295956A (en) | 2022-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022002341A1 (es) | Compuestos y métodos para modular el empalme | |
BR112022017089A2 (pt) | Derivados de piridazina para modular o splicing de ácido nucleico | |
CO2021016018A2 (es) | Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas | |
CO2021016015A2 (es) | Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas | |
CO2022015926A2 (es) | Compuestos y métodos para modular el empalme | |
UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
CL2020001546A1 (es) | Compuestos de 4-azaindol. | |
NI201700095A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
SV2018005794A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
BR112022020423A2 (pt) | Compostos e métodos para modulação de splicing | |
CR20160212A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
CL2019003324A1 (es) | Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745) | |
CO2020002959A2 (es) | Moduladores de piruvato quinasas y uso de los mismos | |
CL2008002132A1 (es) | Compuestos derivados de sulfonamidas, moduladores de trpm8; composiciones farmaceuticas que comprenden a dichos compuestos; y uso de dichos compuestos en el tratamiento del dolor neuropatico, dolor inflamatorio, ansiedad, depresion, hiperalgesia inflamatoria, entre otras. | |
UY35023A (es) | Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso | |
CL2021001461A1 (es) | Moduladores de trex1 | |
CL2016001367A1 (es) | Gamma-dicetonas como activadores de la ruta de señalización de wnt/beta-catenina (divisional de solicitud n° 2363-2015). | |
CO2019006687A2 (es) | Polimorfos | |
CL2017002745A1 (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
CL2023000594A1 (es) | Compuestos heterocíclicos | |
CL2021002093A1 (es) | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x. | |
CL2023003154A1 (es) | Compuestos heterocíclicos | |
ECSP11010807A (es) | Sales de los compuestos del inhibidor de vih | |
CO2022000186A2 (es) | Nuevos compuestos heterocíclicos | |
CO2018001264A2 (es) | Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos |